Spark Investment Management’s Cymabay Therapeutics CBAY Stock Holding History

Spark Investment Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-51,992	Closed	-$76K	–	308
2020 Q1	$76K	Sell	51,992 -218,025	-81%	-$366K	0.04%	299
2019 Q4	$529K	Hold	270,017	–	–	0.06%	340
2019 Q3	$1.38M	Buy	270,017 +27,817	+11%	+$168K	0.18%	146
2019 Q2	$1.73M	Buy	242,200 +58,400	+32%	+$661K	0.12%	213
2019 Q1	$2.44M	Buy	183,800 +59,500	+48%	+$633K	0.11%	220
2018 Q4	$978K	Buy	+124,300	New	+$1.18M	0.07%	320
2015 Q3	–	Sell	-11,300	Closed	-$30K	–	763
2015 Q2	$30K	Sell	11,300 -49,000	-81%	-$201K	﹤0.01%	645
2015 Q1	$417K	Buy	+60,300	New	+$579K	0.06%	409

Other funds holding CBAY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Spark Investment Management's CBAY Position: Q2 2020 in Review

Spark Investment Management sold out of Cymabay Therapeutics (CBAY) in Q2 2020, closing a stake of 51,992 shares — an estimated $76K sold.

Spark Investment Management first reported a position in CBAY in Q1 2015 and held it in 8 quarters. The position peaked at $2.44M in Q1 2019. 114 funds tracked by Wall St. Rank hold CBAY as of Q2 2020.

Spark Investment Management reported no remaining Cymabay Therapeutics position as of Q2 2020 after selling out during the quarter.
Spark Investment Management sold 51,992 Cymabay Therapeutics shares in Q2 2020, an estimated $76K.
Spark Investment Management first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 8 quarters.
Spark Investment Management's Cymabay Therapeutics position peaked at $2.44M in Q1 2019.
114 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.